Role of fibroblast growth factor 23 (FGF2) in Bone Disease in increased urine calcium loss
Not Applicable
- Conditions
- HypercalciuriaC23.888.942.337
- Registration Number
- RBR-8w27x5
- Lead Sponsor
- Faculdade de Medicina da Universidade Federal de Minas Gerais
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Data analysis completed
- Sex
- Not specified
- Target Recruitment
- Not specified
Inclusion Criteria
Pediatric patients; both genders; with diagnosis of Idiopathic Hypercalciuria; age between 3 and 21 years; with diurnal and nocturnal urinary sphincter control.
Exclusion Criteria
Pregnant adolescents; patients with nephrocalcinosis; chronic immobilization; hypercalcemia; history of malignancy; excessive intake of calcium and vitamin D; hyperuricemia; prolonged corticoterapia; renal tubular diseases; use of drugs that interfere with calcium metabolism.
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Expected outcome 1<br>It is expected that levels of fibroblast growth factor are altered in patients diagnosed with idiopathic hypercalciuria, as verified by their plasma dosage by the ELISA method, which will increase their baseline by twice. These levels were measured before treatment in 24 patients and after treatment in 34 patients.<br>;Found outcome 1<br>Fibroblast growth factor levels were found to be significantly altered in patients with Idiopathic Hypercalciuria. Patients with pre-treatment values had FGF23 of 73.0 (32.0-190.0) and those patients with values dosed after treatment of 50.0 (7.0-368.0)<br>p = 0.02
- Secondary Outcome Measures
Name Time Method Secondary outcomes are not expected.